1Zavrski I, Krebbel H, Wildemann B, et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclastfunction [J]. Bioehem Biophys Res Commun, 2005,333 (8) : 200-205.
2Zavrski I,Jakob C,Schmld P,et al. Proteasome: An emergingtarget for cancer therapy [J]. Anti Cancer Drug, 2005,23(3):475-481.
3Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFAL1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation [J]. Blood, 2005,106 (5) : 2470-2483.
4Oshima T,Abe M,Asano J,et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2 [J]. Blood, 2005,107 (6) : 3160-3165.
5Coleman RE ,Major P ,Lipton A .et al. Predictive value of bonc resorption and formation markers in cancer patlents with bonc metastases receiving the bisphosphonatc zoledronic acid[J]. J Clin Oncol, 2005,23 ( 5 ) : 4925-4935.
6Coleman RE, Emerging strategies in bone health management for the adjuvant patient[J]. Semin Oncol.2007,34(6) : 11-16.
7Chung YC,Ku CH,Chao TY.et al. Serum bone biochemical markers in breast cancer with osseous metastasis[J]. Cancer. 2006,15 (3) :424-428.
8Michael G, Alexandrkis A, Aikaterini Sfiridaki B,et al. Relation ship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma[J]. Clin Chim Acta,2007,379(6):31-35.
9Lein M,Wirth M,Miller K,et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression[J]. Eur Urol, 2007,52(4):1381-1387.
10Hirsh V,Major PP,Lipton A,et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity[J]. Thorac Oncol, 2008,3 (2) :228-236.
5Smith DB,Scaffe JH,Eddleston B.The prognostic significance of X-ray changes at presentation and reassessment in patients with multiple myeloma[J].Hematol Oncol,1998,6:1-6.
6Abe M.Hyepercalcemia in myeloma[J].Nippon Rinsbo,2007,65:2245-2249.
7Zannettino AC,Farrugia AN,Kortesidis A,et al.Elevated serum levels of stromal derived factor-1a lphaare associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients[J].Cancer Res,2005,65:1700-1709.
